TACE 联合抗病毒治疗 HBV 相关性肝癌的预后观察及相关因素分析.

To analyze the prognostic factors of transarterial chemoembolization (TACE) combined with antiviral therapy for hepatitis B virus (HBV)-associated hepatocellular carcinoma. This study included 130 patients with HBV-associated hepatocellular carcinoma admitted to the hospital from February 2018 to March 2020. All patients underwent TACE combined with antiviral therapy, and their survival status was recorded. The prognostic factors were analyzed. At the end of follow-up, 58 patients died and 72 patients survived, with a median survival time of 24 months. The 1-year and 2-year survival rates were 82.31% and 55.38%. Univariate analysis and multivariate Cox regression analysis found that the maximum tumor diameter, serum AFP, Child-Pugh grade, abdominal cavity metastasis, and portal vein tumor thrombus were risk factors for poor prognosis. The maximum tumor diameter, serum AFP, Child-Pugh grade, abdominal cavity metastasis, and portal vein tumor thrombus are factors affecting the prognosis of HBV-associated hepatocellular carcinoma treated with TACE combined with antiviral therapy. [ABSTRACT FROM AUTHOR]